We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Arcutis Biotherapeutics Inc | NASDAQ:ARQT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.17 | -2.12% | 7.85 | 7.85 | 12.00 | 8.53 | 7.84 | 8.01 | 2,539,114 | 05:00:05 |
From Nov 2023 to May 2024
By Denny Jacob
Arcutis Biotherapeutics' new drug application for zoryve topical foam as a treatment for seborrheic dermatitis received approval from the Food and Drug Administration.
The early commercial-stage company said the zoryve's approval is for the treatment of seborrheic dermatitis in people ages nine years and older.
Arcutis intends to make zoryve foam widely available through wholesaler and dermatology pharmacy channels as a new treatment option by the end of January.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:34 ET (22:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Arcutis Biotherapeutics Chart |
1 Month Arcutis Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
